跳至主要内容
临床试验/NCT03019302
NCT03019302Unknown不适用

A Study to Determine the Incidence of Catheter-Related Venous Thrombosis When Using Arrow Peripherally-Inserted Central Catheters With Chlorag+Ard Technology

Teleflex4 个研究点 分布在 1 个国家目标入组 100 人开始时间: 2016年12月1日最近更新:
适应症

试验速览

阶段
不适用
发起方
Teleflex
入组人数
100
试验地点
4
主要终点
Incidence of symptomatic and asymptomatic catheter-related venous thrombosis (CVRT)

研究概览

简要总结

A prospective study evaluating the timing, incidence and relationship of commonly occurring complications related to the use of peripherally-inserted central catheters. All subjects will receive PICC access using the Arrow PICC with Chloragard Technology.

研究设计

研究类型
Interventional
分配方式
Na
干预模型
Single Group
主要目的
Supportive Care
盲法
None

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Patients age ≥ 18 years requiring a PICC for a period of fourteen days or greater (note: maximum study period is 90 days)
  • Ability to comply with study requirements inclusive of the follow-up duplex ultrasound procedures and, as applicable, recording of PICC management, interventions and related treatments in the inpatient and outpatient setting in the daily subject diary
  • Patients cognitively and physically able to give written consent to participate in the study or patient has a legally authorized representative (LAR) who may give written consent to participate in the study

排除标准

  • Previous history of (within 3 months) or current diagnosis of venous thrombosis within the venous tract of the proposed catheter
  • History or diagnosis of peripheral or central vein stenosis (on proposed insertion side)
  • History or diagnosis of veno-occlusive disease
  • History or diagnosis of superior vena cava syndrome
  • Known, pre-existing diagnosis of hypercoagulation disorder unrelated to underlying disease
  • Previous enrollment in this study
  • Currently pregnant or breast feeding
  • Previous axillary lymph node dissection on the same side as intended catheter insertion site unless cleared by physician and patient consent
  • Skin condition at or within 15 cm of the proposed catheter insertion site, including signs and symptoms of inflammation, rash, crusts, wounds with drainage, sites of intravenous infusion infiltration or extravasation, hematoma, phlebitis and or thrombophlebitis
  • Medical, social, and/or psychological problems precluding subject from study participation
  • Stage 2, 3 or 4 chronic kidney disease or serum creatinine > 3 mg/dl or Glomerular Filtration Rate (GFR) less than 60 mL per minute per 1.73 m2 unless cleared by a nephrologist for participation
  • Known allergy or sensitivity to chlorhexidine

结局指标

主要结局

Incidence of symptomatic and asymptomatic catheter-related venous thrombosis (CVRT)

时间窗: within maximum 90 days dwell

Incidence of catheter occlusion

时间窗: within maximum 90 days dwell

Incidence of catheter-related bloodstream infections

时间窗: within maximum 90 days dwell

次要结局

未报告次要终点

研究者

发起方
Teleflex
申办方类型
Industry
责任方
Sponsor

研究点 (4)

Loading locations...

相似试验

Arrow Chloragard Peripherally-Inserted Central... | 临床试验